References
- Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol; 2020;95:548–567.
- Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol. 2013;88:168–177. doi:https://doi.org/10.1016/j.critrevonc.2013.04.003.
- van de Donk NWCJ, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410–427. doi:https://doi.org/10.1016/S0140-6736(21)00135-5.
- Loda M, Mucci LA, Mittelstadt ML, et al. Pathology and epidemiology of cancer. Springer. [place unknown]; 2017. pp. 156–166.
- Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 1999;258:583–591. doi:https://doi.org/10.1006/bbrc.1999.0683.
- Kyle RA. Multiple myeloma. Review of 869 cases. Mayo Clin Proc. 1975;50:29–40.
- Ciolli S. Multiple myeloma. Clin Cases Miner Bone Metab. 2012;9:150–152.
- Figueiredo A, Kassis R, Albacker R, et al. The impact of multiple myeloma induction therapy on hematopoietic stem cell mobilization and collection: 25-year experience. Hematol Transfus Cell Ther. 2019;41:285–291. doi:https://doi.org/10.1016/j.htct.2019.03.005.
- Jingping H, Wei-Xin H. Targeting signaling pathways in multiple myeloma: pathogenesis and implication for treatments. Cancer Lett. 2018;414:214–221. doi:https://doi.org/10.1016/j.canlet.2017.11.020.
- Craddock C, Chakraverty R. Stem cell transplantation. Postgrad Haematol Seventh Ed. 2015: 651–675.
- Kumar L, Ramavath D, Kataria B, et al. High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: predictors of long-term outcome. Indian J Med Res. 2019;149:730–739. doi:https://doi.org/10.4103/ijmr.IJMR_1593_18.
- McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770–1781. doi:https://doi.org/10.1056/NEJMoa1114083.
- Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112:1329–1337. doi:https://doi.org/10.1182/blood-2007-08-107292.
- Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma. Clin Cancer Res. 2018;24:106–119. doi:https://doi.org/10.1158/1078-0432.CCR-17-0344.
- Stark S, Watzl C. 2B4 (CD244), NTB-A and CRACC (CS1) stimulate cytotoxicity but no proliferation in human NK cells. Int. Immunol. 2006;18:241–247. doi:https://doi.org/10.1093/intimm/dxh358.
- Zamagni E, Tacchetti P, Pantani L, et al. Anti-CD38 and anti- SLAMF7: the future of myeloma immunotherapy. Expert Rev. Hematol. 2018;11:423–435. doi:https://doi.org/10.1080/17474086.2018.1456331.
- Sherbenou DW, Mark TM, Forsberg P. Monoclonal antibodies in multiple myeloma: a new wave of the future. Clinical Lymphoma Myeloma and Leukemia. 2017;17:545–554. doi:https://doi.org/10.1016/j.clml.2017.06.030.
- Cruz-Munoz ME, Dong Z, Shi X, et al. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol. 2009;10:297–305. doi:https://doi.org/10.1038/ni.1693.
- Ma CS, Nichols KE, Tangye SG. Regulation of cellular and humoral immune responses by the SLAM and SAP families of molecules. Annu. Rev. Immunol. 2007;25:337–379. doi:https://doi.org/10.1146/annurev.immunol.25.022106.141651.
- Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14:2775–2784. doi:https://doi.org/10.1158/1078-0432.CCR-07-4246.
- Bae J, Prabhala R, Voskertchian A, et al. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015;29:218–229. doi:https://doi.org/10.1038/leu.2014.159.
- Apweiler R. The universal protein resource (UniProt) in 2010. Nucleic Acids Res. 2010;38(Database issue):D142–D148..
- Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303.
- Bienert S, Waterhouse A, de Beer TAP, et al. The SWISS-MODEL repository – new features and functionality. Nucleic Acids Res.. 2017;45:D313–D319.
- Abraham MJ, Murtola T, Schulz R, et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015; 1–2: 19-25. doi:https://doi.org/10.1016/j.softx.2015.06.001
- Aliev AE, Kulke M, Khaneja HS, et al. Motional timescale predictions by molecular dynamics simulations: case study using proline and hydroxyproline sidechain dynamics. Proteins Struct Funct Bioinforma. 2014;82:195–215. doi:https://doi.org/10.1002/prot.24350.
- Gordon JC, Myers JB, Folta T, et al. H++: A server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33(Web Server issue):W368–W371. doi:https://doi.org/10.1093/nar/gki464.
- Price DJ, Brooks CL. A modified TIP3P water potential for simulation with Ewald summation. J Chem Phys. 2004;121:10096–10103. doi:https://doi.org/10.1063/1.1808117.
- Berendsen HJC, Postma JPM, Van Gunsteren WF, et al. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81:3684–3690. doi:https://doi.org/10.1063/1.448118.
- Lovell SC, Davis IW, Arendall WB, et al. Structure validation by Cα geometry: φ, ψ and Cβ deviation. Proteins Struct Funct Genet. 2003;50:437–450. doi:https://doi.org/10.1002/prot.10286.
- Wiederstein M, Sippl MJ. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 2007;35(Web Server issue):W407–W410. doi:https://doi.org/10.1093/nar/gkm290.
- Lipinski CA. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004;1:337–341. doi:https://doi.org/10.1016/j.ddtec.2004.11.007.
- Discovery studio. San Diego: Accelrys Inc.; 2014.
- Shashidhar NR, Martha SH, Kulkarni A, et al. Validation studies of the site-directed docking program LibDock. J Chem Inf Model. 2007;47:2159–2217. doi:https://doi.org/10.1021/ci6004299.
- Bhat R, Eissmann P, Endt J, et al. Fine-tuning of immune responses by SLAM-related receptors. J Leukoc Biol. 2006;79:417–424. doi:https://doi.org/10.1189/jlb.0905537.
- Murphy JJ, Hobby P, Vilarino-Varela J, et al. A novel immunoglobulin superfamily receptor (19A) related to CD2 is expressed on activated lymphocytes and promotes homotypic B-cell adhesion. Biochem J. 2002;361:431–436. doi:https://doi.org/10.1042/bj3610431.
- Jh W, Smolyar A, Tan K, et al. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors. Cell. 1999;97:791–803.
- Grigson ER, Ozerova M, Pisklakova A, et al. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner. PLoS One. 2015;10(1):e0117693–15. doi:https://doi.org/10.1371/journal.pone.0117693.
- Robinson MM, Mcbryant SJ, Tsukamoto T, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J. 2007;406(3):407–414.
- Shukla K, Ferraris DV, Thomas AG, et al. Design, synthesis, and pharmacological evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem. 2012;55(23):10551–10563.
- Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–765.
- Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010;18:207–219.
- Effenberger M, Bommert KS, Kunz V, et al. Glutaminase inhibition in multiple myeloma induces apoptosis via MYC degradation. Oncotarget. 2017;8(49):85858–85867. doi:https://doi.org/10.18632/oncotarget.20691.
- Parlati F, Gross M, Janes J, et al. Glutaminase inhibitor CB-839 synergizes with pomalidomide in preclinical multiple myeloma models. Blood. 2014;124(21):4720–4720. doi:https://doi.org/10.1182/blood.V124.21.4720.4720.
- Ghosh N, Rudraraju L, Ye X, et al. Administration of an oral PDE5 inhibitor, tadalafil in conjunction with a lenalidomide containing regimen in patients With multiple myeloma. Blood. 2013;122(21):1959–1959. doi:https://doi.org/10.1182/blood.V122.21.1959.1959.
- Serafini P, Meckel K, Kelso M, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691–2702.
- Noonan K, Ghosh N, Rudraraju L, et al. Targeting immune suppression with PDE5 inhibition in end stage multiple myeloma. Cancer Immunol Res. 2014;2(8):725–731. doi:https://doi.org/10.1158/2326-6066.CIR-13-0213.